US FDA clears Life Spine’s Pro-Link Ti stand-alone cervical spacer system

2783

Life Spine logoLife Spine has announced that the US Food and Drug Administration (FDA) has given 510(k) marketing clearance to the company’s Pro-Link Ti stand-alone cervical spacer system. The system features the company’s Osseo-Loc technology.

“Osseo-Loc is a proprietary surface treatment for titanium with 500-600 microns of porosity, which helps create an environment for potential bone growth,” says Rich Mueller, chief operating officer for Life Spine. “Due to the structural integrity of titanium, we were also able to include lateral graft windows for maximum bone graft volume and visibility.”

Pro-Link Ti is scheduled for full product release by the end of 2016, and joins Life Spine’s portfolio of twenty products launching in 2016.